Scientists Triple Life-Saving Stem-Cell Production

Margaret Munro, CanWest News Service, Edmonton Journal

A life-saving stem-cell treatment has been given a boost by Canadian scientists, who've hit on a way to enhance production of the fabled cells. The team at the University of Western Ontario has shown an experimental drug can expand populations of stem cells in umbilical cord blood up to three times...


Read more

Pluristem Announces Breakthrough in Bone Marrow Transplants: Engrafted Cells Increase 2-4 Times in Preclinical Study


Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy company dedicated to the commercialization of stem cell products, today announced promising initial results of an animal model study using the company's innovative adjuvant cell therapy product known as PLX-1. PLX-1, by adding Mesenchymal Stromal Cells (MSC) during bone marrow transplant procedures that use...


Read more

ViaCell Announces Completion Of CB001 Phase I Clinical Trial

ViaCell, Inc. (Nasdaq: VIAC) today announced that it has enrolled and treated the last patient in the CB001 Phase I clinical trial and has begun the 100-day post-transplant follow-up. CB001 is an investigational therapy being studied as a potential therapeutic option for people who need stem cell transplants, such as bone marrow, for hematopoietic recovery after...


Read more

Expanded cord blood cells hold hope for leukemia patients


Clinical Research Division scientists have cleared a major technical hurdle to making umbilical cord blood transplants a more widely used method for treating leukemia and other blood cancers.


In a study published in the Jan. 17 edition of Nature Medicine, Dr. Colleen Delaney and colleagues describe the first use of a method to vastly expand the number of stem/progenitor cells from a unit of cord blood in the laboratory. When the cells were infused into patients, successful and rapid engraftment resulted.


Read more

5 Spanish centers join a study for a new leukemia and lymphoma treatment technique

The trial is assessing the safety and efficacy of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization trial. StemEx is a graft of expanded stem/progenitor cells, derived from a single unit of umbilical cord blood and transplanted in combination with non expanded cells from the same unit...


Read more